v3.26.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2026
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]  
Schedule of Financial Assets and Liabilities

As of March 31, 2026

 

   Level 1   Level 2   Level 3   Total 
Assets:                
Digital assets — BTC  $66,552,480    
-
    
-
    66,552,480 
Digital assets — USDT  $6,491,176    
-
    
-
    6,491,176 
Digital assets — NILA Tokens  $-    54,771,517    
-
    54,771,517 
Total assets at fair value  $73,043,656    54,771,517    
-
    127,815,173 
                     
Liabilities:                    
Warrant liabilities   
-
    
-
    
-
    
-
 
Derivative liability  $
-
         1,568,634    1,568,634 
Total liabilities at fair value  $
-
    
-
    
-
    1,568,634 

 

As of December 31, 2025

 

Assets:                
Digital assets — BTC  $88,318,950    
-
    
-
    88,318,950 
Digital assets — USDT  $6,484,632    
-
    
-
    6,484,632 
Digital assets — NILA Tokens  $
-
    55,081,789    
-
    55,081,789 
Total assets at fair value  $94,803,582    55,081,789    
-
    149,885,371 
                     
Liabilities:                    
Warrant liabilities   
-
    
-
    
-
    
-
 
Derivative liability  $
-
         1,616,913    1,616,913 
Total liabilities at fair value  $
-
    
-
    
-
    1,616,913 
Schedule of Fair Value on Recurring Basis

For the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the following table provides a reconciliation of the beginning and ending balance for each category therein, and gains or losses recognized during the three ended March 31, 2026:

 

Balance – December 31, 2025  $1,616,913 
Change in fair value of derivative liability   (48,279)
Ending balance – March 31, 2026  $1,568,634 

 

  

March 31,

2026

(Issuance

Remeasurement)

 
   Derivative Liability 
Fair Value  $1,568,634 
Valuation technique   Monte Carlo Simulation Model 
Schedule of Segmented Assets

For the three months ended March 31, 2026

 

   BioBusiness
Segment		   Digital Asset
Segment		   Corporate   Consolidated 
Revenue  $
-
   $
-
   $
-
   $
-
 
                     
Operating expenses:                    
Research and development   901,144    
-
    
-
    901,144 
General and administrative   1,378,074    1,660,921    8,245,555    11,284,550 
Total operating expenses  $2,279,218   $1,660,921   $8,245,555   $12,185,694 
Loss from operations   (2,279,218)   (1,660,921)   (8,245,555)   (12,185,694)
                     
Other income (expense), net:                    
Realized gain on sale of digital assets   
-
    15,100    
-
    15,100 
Trading gains, net   
-
    2,029    
-
    2,029 
Unrealized gain (loss) on digital assets   
-
    (22,078,601)   
-
    (22,078,601)
Change in FV of derivative   
-
    
-
    48,279    48,279 
Change in FV of warrant liability   
-
    
-
    
-
    
-
 
Interest income   
-
    
-
    7    7 
Interest expense   (2,222)   
-
    (857,183)   (859,405)
Foreign currency transaction loss   
-
    (1,567)   
-
    (1,567)
Total other income (expense), net  $(2,222)  $(22,063,039)  $(808,897)  $(22,874,158)
Net loss  $(2,281,440)  $(23,723,960)  $(9,054,452)  $(35,059,852)

For the three months ended March 31, 2025

 

  

BioBusiness

Segment

  

Digital Asset

Segment

   Corporate   Consolidated 
Revenue  $
-
   $
    -
   $
     -
   $
       -
 
                     
Operating expenses:                    
Research and development   
 
    -    -    
 
 
General and administrative   364,368    
-
    
-
    364,368 
Total operating expenses  $364,368   $    $    $364,368 
Loss from operations   (364,368)             (364,368)
                     
Other income (expense), net:   -    -           
Realized gain on sale of digital assets   
-
    
-
    
-
    
 
 
Trading gains, net   
-
    
 
    
-
    
-
 
Unrealized gain (loss) on digital assets   
-
    
-
    
-
    
-
 
Change in FV of derivative   
-
    
-
    
-
    
-
 
Change in FV of warrant liability   
-
    
-
    
-
    
-
 
Interest income   
-
    
-
    3    3 
Interest expense   
 
    
-
    (38,032)   (38,032)
Foreign currency transaction loss   
-
    
-
    
-
    
-
 
Total other income (expense), net  $
-
   $
-
   $(38,029)  $(38,029)
Net loss  $(364,368)  $
-
   $(38,029)  $(402,397)
Schedule of Segmented Assets

As of March 31, 2026

 

   BioBusiness   Digital Asset         
   Segment   Segment   Corporate   Consolidated 
Cash & Cash Equivalents  $921,284   $55,704   $2,546   $979,534 
Restricted Cash   
-
    
-
    8,000,000    8,000,000 
Short Term Investments   1,500,000    
-
    
-
    1,500,000 
Prepaid Expenses   2,647,579    
-
    
-
    2,647,579 
Digital assets, at fair value   
-
    127,815,173    
-
    127,815,173 
Other Assets   228,371    
-
    48,500    276,871 
Total Assets  $5,297,234   $127,870,877   $8,051,046   $141,219,157 

 

As of December 31, 2025

 

   BioBusiness   Digital Asset         
   Segment   Segment   Corporate   Consolidated 
Cash & Cash Equivalents  $1,492,054   $144,600   $
-
   $1,636,654 
Restricted Cash   
-
    
-
    8,000,000    8,000,000 
Short Term Investments   2,000,000    
-
    
-
    2,000,000 
Prepaid Expenses   2,374,189    
-
    
-
    2,374,189 
Digital assets, at fair value   
-
    149,885,371    
-
    149,885,371 
Other Assets   239,021    
-
    48,500    287,521 
Total Assets  $6,105,264   $150,029,971   $8,048,500   $164,183,736 
Schedule of Antidilutive Potential Shares of Common Stock

The following table sets forth the number of potential shares of common stock that have been excluded from basic net loss per share because their effect was anti-dilutive:

 

   March 31,
2026		   March 31,
2025		 
Series A convertible preferred shares (1:20 conversion ratio)   149,540,340      
Stock options   512,620    213,693 
Warrants   1,116,913      
Convertible notes   8,307,927    295,672 
Total anti-dilutive shares excluded   159,477,800    509,365